Clinical trial
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00128713 · Carelon Research, Other · Completed
Key facts
| NCT number | NCT00128713 |
|---|---|
| Title | Optimal Platelet Dose Strategy for Management of Thrombocytopenia |
| Official title | Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study) |
| Acronym | PLADO |
| Lead sponsor | Carelon Research, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH Transfusion Medicine/Hemostasis Clinical Research Network |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thrombocytopenia |
| Intervention type | Procedure |
| Interventions | Medium Dose Prophylactic Platelet Transfusions, Lower Dose Prophylactic Platelet Transfusions, Higher Dose Prophylactic Platelet Transfusions |
| Enrollment | 1,351 |
| Start date | Jul 1, 2004 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Aug 10, 2005 |
| Last update posted | Oct 28, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: